此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Effect of Stellate Ganglion Block on Sleep Quality in Patients With Depression

2026年10月8日 更新者:Li Juan

# Brief Summary

This clinical research study looks at whether stellate ganglion block (SGB) can improve sleep quality for people with depression. Poor sleep often goes together with depression. Medicines used for these conditions may cause side-effects or dependency. Researchers want to learn if SGB, a minimally-invasive nerve treatment, can help sleep and mood without those medicine-related downsides.

This study uses a self-controlled design. Every person who joins will receive the study treatment. No separate comparison group is enrolled. Researchers will collect sleep data from each participant before treatment and again after treatment, then compare these two sets of information.

About 42 participants will take part in this study.

Key requirements to join the study:

  • Aged 18 to 65 years old
  • Have depression-related symptoms and sleep trouble
  • Able to understand and sign an informed consent form
  • No medical conditions that make SGB unsafe
  • Have not taken sleep-affecting medicines or received other sleep-focused treatments in the past one month
  • Can follow study schedules and complete all study assessments

People cannot join if they:

  • Are younger than 18 years or older than 65 years
  • Are pregnant or breastfeeding
  • Have known allergies to study-used medicines
  • Have unstable serious organ diseases, uncontrolled substance or alcohol dependence
  • Cannot keep fixed daily routines or finish all study visits

Study procedures for each participant:

  1. On study day zero (D0): Study staff will explain the study fully. Participants will sign informed consent. Staff will run physical checks and blood tests. Participants will fill out several simple questionnaires about mood and sleep. Sleep will be measured overnight with a multi-channel sleep recording device called polysomnography (PSG). Participants also keep a short sleep diary.
  2. From study day one (D1) to day five (D5): Participants get one SGB treatment each day, for a total of five treatments. During SGB, a doctor uses ultrasound guidance to inject small-dose local anesthetic near nerves in the neck. Participants keep completing their sleep diary every day. Study staff watch for any unwanted reactions during each treatment.
  3. On the night of D5 through early morning of D6: PSG sleep recording will be repeated after the final SGB treatment.
  4. On study day six (D6): Participants finish the final set of mood-and-sleep questionnaires. Study staff collect all safety information.

Researchers will compare sleep measurements taken before treatment versus after five-day SGB treatment. Collected data includes objective sleep readings from PSG and self-reported sleep information from sleep diaries. Questionnaires will show changes in depression and insomnia symptoms.

Possible benefits: SGB may make participants' sleep better and may ease depression-related symptoms. No benefit is guaranteed for every participant.

Possible risks: SGB is generally safe. Rare unwanted reactions may include temporary hoarseness, local neck-site infection, or drug allergic responses. Study doctors will watch participants closely. If serious problems happen, immediate medical help will be provided.

All participants' private personal information will be protected. Participants can choose to stop taking part in this research at any time without penalty.

研究概览

地位

尚未招聘

条件

干预/治疗

研究类型

介入性

注册 (估计的)

42

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 至 65年 (成人、年长者)

接受健康志愿者

是的

有资格学习的性别

全部

描述

Inclusion Criteria:

  1. Aged 18-65 years of both genders. Alert and capable of normal communication. Voluntarily sign informed consent, complete the whole experimental procedure, and meet ethical and compliance requirements.
  2. Hamilton Depression Rating Scale (HAMD) score ≥ 8.
  3. Insomnia Severity Index (ISI) score ≥ 7 or Pittsburgh Sleep Quality Index (PSQI) score ≥ 7.
  4. No contraindications to stellate ganglion block (SGB); no cervical deformity, trauma, or infection; and no severe cervical spine disease, such as cervical fracture or cervical disc herniation with nerve compression.
  5. No use of sedative-hypnotics, anxiolytics, antidepressants, or other medications that may affect sleep within the past month, and no acupuncture, massage, nerve block, or other sleep-related interventions during the same period.
  6. Stable vital signs; normal liver and renal function, complete blood count, and coagulation function; and no severe organic diseases of the heart, brain, lungs, liver, or kidneys.
  7. Able to strictly follow the required sleep-wake schedule and cooperate with polysomnography (PSG) monitoring and completion of sleep diaries, with good study compliance.

Exclusion Criteria:

  • 1: Age <18 or >65 years; pregnant or lactating women; subjects with psychiatric disorders (schizophrenia, mania, etc.) or cognitive impairment who cannot cooperate with the study, to prevent missing data and experimental bias.

    2: Presence of contraindications to stellate ganglion block, such as coagulation disorders, local skin infection, severe cervical spine disease, hyperthyroidism, glaucoma, or increased intracranial pressure.

    3: Allergy to ropivacaine, epinephrine, or other drugs used for the block, or a history of drug allergy.

    4: Use of sedative-hypnotics, anxiolytics, antidepressants, hormonal medications, or other treatments that may affect sleep within the past month.

    5: Severe cardiovascular or cerebrovascular disease, hepatic or renal insufficiency, hematologic disease, respiratory disease, or other serious organic diseases, or a recent history of surgery or trauma.

    6: Alcohol dependence or drug dependence, or daily consumption of coffee, strong tea, or other stimulating beverages with inability to abstain during the study period.

    7: Inability to maintain a fixed sleep-wake schedule during the study or inability to complete the full monitoring and intervention procedures because of work, daily life, or other reasons.

    8: Voluntary withdrawal during the study, or inability to complete the study because of adverse reactions, poor compliance, or other reasons.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:不适用
  • 介入模型:单组作业
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:SGB group

Stellate Ganglion Block

Using an anterior-lateral approach, participants lie supine with head turned contralaterally to expose the neck. The interspace between the anterior sternocleidomastoid border, trachea and common carotid artery is identified. Skin is disinfected 3 times with iodophor (≥15 cm diameter), then covered with a sterile aperture drape.

A 22-G needle is inserted vertically at the target site. After bony contact with the C6 transverse process, the needle is retracted 0.1-0.2 cm. With negative aspiration for blood and cerebrospinal fluid, inject 6 mL 0.25% ropivacaine (epinephrine 1:200 000) at 1 mL/min to limit bleeding and prolong block effect.

Monitor blood pressure, heart rate, oxygen saturation, and adverse events (hoarseness, Horner syndrome, dyspnea) throughout injection.

研究衡量的是什么?

主要结果指标

结果测量
大体时间
Sleep Onset Latency, SOL
大体时间:At baseline (Day 0) and from Night 5 to Morning 6 after intervention
At baseline (Day 0) and from Night 5 to Morning 6 after intervention
Wake After Sleep Onset, WASO
大体时间:At baseline (Day 0) and from Night 5 to Morning 6 after intervention
At baseline (Day 0) and from Night 5 to Morning 6 after intervention
Total Sleep Time, TST
大体时间:At baseline (Day 0) and from Night 5 to Morning 6 after intervention
At baseline (Day 0) and from Night 5 to Morning 6 after intervention
Proportions of each non-rapid eye movement sleep stage
大体时间:At baseline (Day 0) and from Night 5 to Morning 6 after intervention
At baseline (Day 0) and from Night 5 to Morning 6 after intervention
Proportions of REM, NREM and Wake
大体时间:At baseline (Day 0) and from Night 5 to Morning 6 after intervention
At baseline (Day 0) and from Night 5 to Morning 6 after intervention
Sleep Efficiency, SE
大体时间:At baseline (Day 0) and from Night 5 to Morning 6 after intervention
At baseline (Day 0) and from Night 5 to Morning 6 after intervention

次要结果测量

结果测量
大体时间
Subjective sleep-onset latency
大体时间:30 minutes after awakening on the corresponding next morning
30 minutes after awakening on the corresponding next morning
Subjective Total Sleep Time
大体时间:30 minutes after awakening on the corresponding next morning
30 minutes after awakening on the corresponding next morning
Subjective Sleep Efficiency
大体时间:30 minutes after awakening on the corresponding next morning
30 minutes after awakening on the corresponding next morning
Sleep Satisfaction
大体时间:30 minutes after awakening on the corresponding next morning
30 minutes after awakening on the corresponding next morning

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

赞助

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (估计的)

2026年9月20日

初级完成 (估计的)

2026年12月1日

研究完成 (估计的)

2026年12月30日

研究注册日期

首次提交

2026年9月7日

首先提交符合 QC 标准的

2026年9月17日

首次发布 (实际的)

2026年9月23日

研究记录更新

最后更新发布 (实际的)

2026年10月13日

上次提交的符合 QC 标准的更新

2026年10月8日

最后验证

2026年9月1日

更多信息

与本研究相关的术语

其他研究编号

  • BoYi Medical Ethics No.1162026

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

是的

IPD 计划说明

De-identified individual participant data underlying the published results will be available to qualified researchers after article publication. Data access requires a formal research proposal and signed data-use agreement.

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.